How to Buy Monte Rosa Therapeutics, Inc. Common Stock (GLUE) Stock

Where to buy GLUE

13 brokers in our matrix offer GLUE. Verify availability and current fees with each broker before trading.

Broker	Commission	Fractional	Extended	Overnight	Options	OTC access
Charles Schwab (thinkorswim)Review	$0	Schwab Stock Slices, S&P 500 only, ≥ $5/slice, up to 30 at once		~1,130	$0.65	Most (3/5)
E*TRADE (Morgan Stanley)Review	$0 listed			~20	$0.65	Most (4/5)
FidelityReview	$0	Stocks by the Slice, 7,000+ stocks/ETFs, from $1			$0.65	Partial (2+0)
FirstradeReview	$0	~4,000+ tickers, ≥ $5		~1,200	$0	Most (4/5)
Interactive BrokersReview	$0 (Lite) / per-share (Pro)			~10,000	per-contract pricing	Full
Merrill EdgeReview	$0				$0.65	Most (3/5)
MoomooReview	$0				$0	Limited only
Public.comReview	$0				rebate model	Limited only
RobinhoodReview	$0	≥ $1 stocks, market cap ≥ $25M		~1,134	$0	None
SoFi Active InvestingReview	$0				$0	Partial (1+2)
tastytradeReview	$0 stocks				$1.00 open, $0 close (capped at $10 per leg)	Limited only
TradeStationReview	$0 listed				$0.50 / $0.60	Most (4/5)
WebullReview	$0				$0	Limited only

24-Hour / Overnight trading

GLUE may be eligible for overnight trading via Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), Webull, Moomoo, Firstrade. Each broker maintains its own eligibility list — confirm before placing an order.

About Monte Rosa Therapeutics, Inc. Common Stock

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Employees

161

Headquarters

BOSTON, MA

Listed

2021-06-24

Market cap

$1.58B

Frequently asked

Where can I buy Monte Rosa Therapeutics, Inc. Common Stock (GLUE)?

GLUE is offered by 13 brokers in our matrix, including Charles Schwab (thinkorswim), E*TRADE (Morgan Stanley), Fidelity, Firstrade, Interactive Brokers. Compare commissions, fractional eligibility, and overnight availability in the broker matrix above.

Can I buy GLUE after hours or overnight?

Yes. GLUE is on the 24-hour eligibility list for Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), and others. Overnight sessions route through ATSs with wider spreads and limit-orders only.

Does Robinhood offer GLUE?

Yes. Robinhood offers GLUE as a regular exchange-listed security.

Does Fidelity offer GLUE?

Yes. Fidelity offers GLUE as a regular exchange-listed security.

Does Webull offer GLUE?

Yes. Webull offers GLUE as a regular exchange-listed security.

Is GLUE optionable?

Yes. GLUE has listed options contracts. Per-contract pricing varies by broker — see the Options column in the matrix.

Is there a tokenized version of GLUE?

Not in our current dataset. The tokenized stock universe (Kraken xStocks, Binance Alpha/Ondo, Robinhood EU, Hyperliquid HIP-3) is expanding quickly — we refresh quarterly.

Can I buy a fractional share of GLUE?

Yes. Multiple brokers in the matrix support fractional shares for GLUE — see the Fractional column above for per-broker eligibility and minimums.